Second-line Chemotherapy for Advanced Bladder Cancer: Taxanes Versus Vinflunine
Aim: Second-line chemotherapy in advanced urothelial carcinoma (UC) remains a significant clinical challenge, with limited high-level evidence guiding regimen selection. Vinflunine is the only agent approved by the European Medicines Agency for this setting, while taxanes are widely used off-label b...
Saved in:
| Main Authors: | Bilgin Demir, Ali Aytaç, Gökhan Çolak, Onur Yazdan Balçık, Ömer Acar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2025-08-01
|
| Series: | Acta Haematologica Oncologica Turcica |
| Subjects: | |
| Online Access: | https://www.actaoncologicaturcica.com/articles/second-line-chemotherapy-for-advanced-bladder-cancer-taxanes-versus-vinflunine/doi/ahot.galenos.2025.2025-7-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab
by: Toshihiko Matsumoto, et al.
Published: (2025-08-01) -
Establishment and Genetic Profiling of Platinum/Taxane Doublet-Resistant Cells Generated by Hybridizing Single Resistant Cells
by: Seiji Isonishi, et al.
Published: (2022-09-01) -
CNA landscape of HER2-negative breast cancer during administration of taxane-containing schemes of neoadjuvant chemotherapy
by: M. K. Ibragimova, et al.
Published: (2025-04-01) -
Modern approaches to drug therapy of bladder cancer after first progression.
by: L. V. Bolotina, et al.
Published: (2015-06-01) -
Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial
by: Elena López-Miranda, et al.
Published: (2025-08-01)